TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01091272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04995274
Description: Planned single PO 0.15mg, 1.5mg, 15mg doses of PF-04995274 interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04995274
Description: Planned single PO 0.5mg, 5mg, 50mg doses of PF-04995274, interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg.
Study: NCT02433405

Intervention type: BIOLOGICAL
Intervention: Serum Amyloid A
Description: Acute phase protein
Study: NCT02731807

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose A: TA-65 24mg, powder

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose A: TA-65 24mg, powder

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose B: TA-65, 8mg, powder

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose B: TA-65, 8mg, powder

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose B: TA-65, 8mg, powder

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose B: TA-65, 8mg, powder

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose C: TA-65 3.2mg, capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose C: TA-65 3.2mg, capsule
Study: NCT02441881

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Induced Thermal Therapy
Description: Endovenous radiofrequency device
Study: NCT02433405

Intervention type: BIOLOGICAL
Intervention: Serum Amyloid A
Description: Acute phase protein

Intervention type: BIOLOGICAL
Intervention: Serum Amyloid A
Description: Acute phase protein
Study: NCT01355757

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baxter INFUSOR System
Description: Regional Analgesia INFUSOR system with Patient Control Module for post-operative analgesia
Study: NCT02731807

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose C: TA-65 3.2mg, capsule
Study: NCT02441881

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endovenous Radiofrequency
Description: Endovenous radiofrequency device
Study: NCT02731807

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose C: TA-65 3.2mg, capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose D: TA-65 8mg, capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose D: TA-65 8mg, capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose D: TA-65 8mg, capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose D: TA-65 8mg, capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose E: TA-65 32mg, capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose E: TA-65 32mg, capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose E: TA-65 32mg, capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose E: TA-65 32mg, capsule
Study: NCT01413841

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasal oxygen
Description: 3 l oxygen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Regular nasal air
Description: 3 l nasal air
Study: NCT02289404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1203
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1203
Description: Oral
Study: NCT00384826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Erlotinib 150 mg/day (until progression)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel + carboplatine
Description: Paclitaxel 90 mg/m² D1, D8, D15 (D1=D28, until progression) Carboplatine AUC 6 D1 (D1=D28, 6 cycles)
Study: NCT03431701

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Vaginal cleansing will be performed in conjunction with the abdominal preparation with foam sponge that contains chlorhexidine. A sponge soaked with chlorhexidine will be inserted into the vagina and rotated 360 degrees in the vaginal cavity for about 30 seconds

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Iodine
Description: Vaginal cleansing will be performed in conjunction with the abdominal preparation with foam sponge that contains iodine. A sponge soaked with iodine will be inserted into the vagina and rotated 360 degrees in the vaginal cavity for about 30 seconds

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: All participants will receive a single body mass index (BMI) based antibiotic dose of cefazolin or clindamycin within 30 minutes prior to the incision.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: All participants will receive a single body mass index (BMI) based antibiotic dose of cefazolin or clindamycin within 30 minutes prior to the incision.
Study: NCT00675103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegloticase 8 mg i.v.
Description: pegloticase 8 mg i.v. every 2 weeks for 24 weeks
Study: NCT02462733

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tools of the Mind (TOM)
Description: TOM is play-based but features explicit, scripted, teacher-directed activities aimed specifically at helping to improve children's self-control skills. Early evidence supports the program efficacy and suggests benefits for children's development more generally (including language, reading and mathematics).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Playing to Learn (PTL)
Description: PTl is a play based preschool program now in wide use in YMCA childcare settings across Canada (and some in the United States). The activities in PTL are child initiated and are not prescribed. Teachers are trained to observe children at play and to capitalize on learning opportunities as they arise.
Study: NCT01790711

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FMT through mid-gut
Study: NCT00190983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed: 900 mg/m2 (700 mg/m2 for patients with prior radiotherapy) intravenous (IV) over 10 minutes every 21 days until disease progression.
Study: NCT04408066

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sample Collection/Performance Evaluation (A)
Description: This is a prospective sample collection and performance evaluation study which involves no therapeutic intervention.~Sample types include:~* Nasal/Throat/Nasal Throat Combo/ Nasopharyngeal (as per sites SOC) Swab~* Whole Venous Blood

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sample Collection/Performance Evaluation (B)
Description: This is a prospective sample collection and performance evaluation study which involves no therapeutic intervention.~Sample types include:~* Whole Venous Blood~* Fingerstick Capillary Sample
Study: NCT01573013

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: iron fortified biscuits
Description: 10 mg of iron per day for 8 months, either in the form of NaFeEDTA

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: iron fortified biscuits
Description: 10 mg of iron per day for 8 months, in the form of FeSo4

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: iron fortified biscuits
Description: EDTA fortified biscuit on a daily basis for 8 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: iron fortified biscuits
Description: control biscuit on a daily basis for 8 months
Study: NCT03828149

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Drug:OP0201
Description: Drug: OP0201

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Drug: Placebo
Description: Drug: Placebo
Study: NCT01213095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: rituximab 375mg/m2, every 8 weeks, 12 times
Study: NCT04089813

Intervention type: DRUG
Intervention: Metformin
Description: Patients use metformin to control blood sugar
Study: NCT02652507

Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: 2 mc/kg/h over ten minutes followed by a continuous infusion of 2 mcg/kg/h
Study: NCT03399916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prompt sent
Study: NCT01388881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Education
Description: The intervention - music classes - will be methodologically and educationally based on the National Curriculum Parameters that were developed in Brazilian in the 80s; the focus here is centered on a modern approach to music education where the traditional process of musical learning is not restricted to the domain of the musical reading (sheet music), but also includes musical improvisation, composition and interpretation. Children will be encouraged to create their own music; perception and identification of the elements of musical language in production activities will be explained to them by means of voice, body, sound materials and tools available. Song lyrics, rhymes and rap will be created using elements of musical language not focused purely on the classical elements/music.
Study: NCT01387906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical bimatoprost
Description: topical bimatoprost will be applied one drop to each eyebrow each night.
Study: NCT01404182

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with Fluval AB influenza vaccine
Description: Vaccination with a single dose of Fluval AB influenza vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/0.5mL of seasonal H1N1, H3N2 and B influenza antigens each) and aluminium phosphate gel adjuvant.
Study: NCT02274142

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restoration with hand-mixed material
Description: restoration with hand-mixed glass ionomer cement
Study: NCT02652507

Intervention type: DRUG
Group type: OTHER
Intervention: Ketamine
Description: Bolus dose 2 mg/kg after first set of research images are obtained
Study: NCT01415856

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Device (Torino II)
Description: Device is giving treatment for 15 minutes every 2 hours for a total of two weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Device (Torino II)
Description: Device is designed to appear to be giving treatment when it is not actually giving treatment. Patients will wear this for a duration of two weeks.
Study: NCT05605483

Intervention type: OTHER
Intervention: Salad bar
Description: Schools where the school district has installed salad bars

Intervention type: OTHER
Intervention: Waitlisted control
Description: Schools where the school district has not yet installed salad bars

Intervention type: OTHER
Intervention: Salad bar post-COVID
Description: Schools where the school distract has re-opened salad bars will have methods repeated in a subset of schools post-COVID-19
Study: NCT03212664

Intervention type: OTHER
Group type: OTHER
Intervention: exercise
Description: physical therapy exercises
Study: NCT00805545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic
Description: Cefazolin 1gm Intravenously and Azithromycin 500mg Intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic
Description: Cefazolin 1gm Intravenously and Azithromycin 500mg Intravenously
Study: NCT01628094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5024048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5190591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5190591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5190591
Study: NCT01091272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04995274
Description: Planned single PO 120mg and 210mg doses of PF-04995274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04995274
Description: single PO dose of PF-04995274; dosage to be determined by safety and pharmacokinetic data
Study: NCT02274142

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restoration with Encapsulated material
Description: restoration with encapsulated ionomer cement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Encapsulated glass ionomer cement (EQUIA - GC Corp).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: powder-liquid glass ionomer cement (Fuji IX - GC Corp)
Study: NCT01628094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5190591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5190591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5190591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5466731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5466731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5466731
Study: NCT01457612

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Strawberry
Description: 20g twice per day (BID) in beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo1
Description: Placebo Beverage 1 without fiber

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo2
Description: Placebo Beverage 2 with Fiber
Study: NCT01628094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5466731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5466731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5466731
Study: NCT00551577

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant chemotherapy (Carboplatin/Docetaxel)
Description: 3 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 3 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
Study: NCT01628094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Study: NCT05369026

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single leg immobilization
Description: 2 weeks of single-leg immobilization

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Single leg immobilization
Description: 2 weeks of single-leg immobilization
Study: NCT01284270

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiac MRI
Description: Cardiac MRI
Study: NCT04426370

Intervention type: OTHER
Intervention: Observational
Description: Physical examination and questionnaires

Intervention type: OTHER
Intervention: Observational
Description: Physical examination and questionnaires
Study: NCT04070170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level Laser Therapy
Description: Low-level laser therapy is applied on premolars that will be extracted for treatment plan reasons

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level Laser Therapy
Description: Low-level laser therapy is applied on premolars that will be extracted for treatment plan reasons

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level Laser Therapy
Description: Low-level laser therapy is applied on premolars that will be extracted for treatment plan reasons

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthodontic force
Description: Mechanical loading is applied on premolars that will be extracted for treatment plan reasons and in canines for tooth movement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthodontic force
Description: Mechanical loading is applied on premolars that will be extracted for treatment plan reasons and in canines for tooth movement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic force
Description: Mechanical loading is applied on premolars that will be extracted for treatment plan reasons and in canines for tooth movement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic force
Description: Mechanical loading is applied on premolars that will be extracted for treatment plan reasons and in canines for tooth movement
Study: NCT04602676

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rehydration calculator application with DEP algorithm
Description: 4 week period where clinicians will use a rehydration calculator application with the DEP algorithm followed by a 1 week washout period.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rehydration calculator application with DEP algorithm
Description: 4 week period where clinicians will use a rehydration calculator application with the DEP algorithm followed by a 1 week washout period.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rehydration calculator application
Description: 4 week period where clinicians will use a rehydration calculator application without the DEP algorithm followed by a 1 week washout period.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rehydration calculator application
Description: 4 week period where clinicians will use a rehydration calculator application without the DEP algorithm followed by a 1 week washout period.
Study: NCT03814590

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine (GSK3844766A) unadjuvanted low dose
Description: Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine (GSK3844766A) unadjuvanted low dose
Description: Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E
Description: Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B
Description: Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine (GSK3844766A) unadjuvanted medium dose
Description: Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine (GSK3844766A) unadjuvanted medium dose
Description: Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E
Description: Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B
Description: Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine (GSK3844766A) unadjuvanted high dose
Description: Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine (GSK3844766A) unadjuvanted high dose
Description: Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E
Description: Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B
Description: Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline solution)
Description: Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline solution)
Description: Two doses administered intramuscularly at Days 1 and 61 in the deltoid region of the arm.
Study: NCT00961922

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: 30 sessions of neurofeedback will be given twice a week at the child's home. It will take about 15 weeks to complete the training.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo feedback
Description: Feedback based on a random signal generator and muscular tension instead of brain activity. 30 sessions at home, twice a week, total 15 weeks.
Study: NCT02843581

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryosurgery
Description: Argon-helium cryosurgical system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Argon-helium cryosurgical system

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK immunotherapy
Description: Nutral killer cell immunotherapy for more than 6 times
Study: NCT01288508

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supra Fiber
Description: 2 tablespoons of fiber taken with 8oz water taken twice a day for 30 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Psyllium
Description: 1 tablespoon of fiber taken with 8 oz water twice a day for 30 days